Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...
Finanznachrichten10d
Cytokinetics, Incorporated: Cytokinetics Announces 2025 Corporate Milestones and Vision 2030
At the same time, we are executing on a robust clinical trials development program for aficamten inclusive of MAPLE-HCM, with results expected in the first half of this year as may potentially support ...
Cytokinetics provided milestones expected in 2025
Cytokinetics (CYTK) provided guidance for corporate milestones expected to occur in 2025. Expected 2025 Milestones: Cardiac Muscle Programs: ...
Aficamten Poised for Best-in-Class Status in oHCM Treatment with Anticipated Phase 3 Data and Promising Trial Results
Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Cytokinetics (CYTK – Research Report) and keeping the price target at ...
Investing16d
Cytokinetics’ SWOT analysis: aficamten progress boosts stock outlook
The MAPLE-HCM trial, which is evaluating aficamten as monotherapy, is expected to complete enrollment in the third quarter of 2024, with results anticipated in the first half of 2025. This study could ...
Investing16d
Cytokinetics' SWOT analysis: aficamten progress boosts stock outlook
The MAPLE-HCM trial, which is evaluating aficamten as monotherapy, is expected to complete enrollment in the third quarter of 2024, with results anticipated in the first half of 2025. This study ...